Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 3933)

## UPDATED INFORMATION OF THE GROUP'S PRODUCTS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Memantine Hydrochloride Tablets (10mg) manufactured by Zhuhai United Laboratories Co., Ltd., Zhongshan Branch (珠海聯邦制藥股份有限公司中山分公司), a wholly-owned subsidiary of the Company, with the approval of China National Medical Products Administration, passed the consistency of quality and efficacy evaluation for generic drugs (the "Consistency Evaluation").

Memantine Hydrochloride is a nervous system drug indicated for the treatment of moderate to severe dementia of the Alzheimer's type, and is listed as Category B in the National Medical Insurance Drug List (2020 Version).

The approval will further facilitate the Company's business expansion in the field of nervous system. The Company will continue to be devoted to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan

Chairman

Hong Kong, 7 June 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.